A benefit–cost analysis of specialty residential treatment (Specialty) and standard residential treatment (Standard) was conducted on a sample of pregnant and parenting substance abusers from Arkansas. Economic benefits were derived from client self–reported information at treatment entry and at 6–month postdischarge with the use of an augmented version of the Addiction Severity Index (ASI). The average cost of treatment in Specialty programs was $8,035 versus $1,467 for Standard residential treatment. Average net benefits (benefit–cost ratios) were estimated to be $17,144 (3.1) for Specialty and $8,090 (6.5) for Standard. The main policy implication of this research is that investment in Specialty residential treatment for pregnant and parenting substance–abusing women appears to be economically justified, but future evaluations should analyze larger and more comparable samples to improve power and precision in the benefit–cost statistics.
LeeMJ. 1998. Marihuana and tobacco use in pregnancy. Obstet Gynecol Clin North Am, 25: 65–83.
2.
BauerCR. 1999. Perinatal effects of prenatal drug exposure, neonatal aspects. Clin Perinat, 26: 87–106.
3.
De VilleKA and KopelmanLM. 1998. Moral and social issues regarding pregnant women who use and abuse drugs. Obstet Gynecol Clin North Am, 25: 237–254.
4.
ReedBG. 1985. Drug misuse and dependency in women: The meaning and implications of being considered a special population or minority group. Int J Addict, 20: 13–62.
5.
National Institute on Drug Abuse. 1996. National Pregnancy and Health Survey: Drug use among women delivering livebirths: 1992, Washington, DC: US Department of Health and Human Services.
6.
DeltaMetrics. 1999. Problem Severity and Treatment Outcomes of Pregnant and Parenting Women in Specialty and Standard Residential Substance Abuse Treatment: Final report, Arkansas: TOPPS I.
7.
FrenchMT, SaloméHJ, KrupskiA, McKayJR, DonovanDM, McLellanAT and DurellJ. 2000. Benefit–cost analysis of residential and outpatient addiction treatment in the state of Washington. Eval Review, 24(6): 609–634.
8.
FrenchMT, SaloméHJ, SindelarJL and McLellanAT. in press. Benefit–Cost Analysis of Substance Abuse Treatment: Methodological Guidelines and Application Using the DATCAP and ASI. Health Services Research,
9.
FrenchMT, SaloméHJ and CarneyM. 2001a. Using the DATCAP and ASI to Estimate the Costs and Benefits of Residential Addiction Treatment in the State of Washington, University of Miami School of Medicine. Working paper
10.
FrenchMT, McCollisterKE, SacksS, McKendrickK and De LeonG. in press. Benefit–cost analysis of a modified therapeutic community for mentally ill Chemical Abusers. Evaluation and Program Planning,
11.
CartwrightWS. 1998. Cost–benefit and cost–effectiveness analysis of drug abuse treatment services. Eval Rev, 22: 609–636.
12.
FrenchMT. 1995. Economic evaluation of drug abuse treatment programs: Methodology and findings. Am J Drug Abuse, 21: 111–135.
GoldMR, SiegelJE, RussellLB and WeinsteinMC. 1996. Cost–Effectiveness in Health and Medicine, New York: Oxford University Press.
15.
DrummondMF, O'BrienCP, StoddartGL and TorranceGW. 1997. Methods for the Economic Evaluation of Health Care Programmes, New York: Oxford University Press.
16.
KenkelD. 1997. On valuing morbidity, cost–effectiveness analysis, and being rude. J Health Econ, 16: 749–757.
17.
SindelarJL and ManningWG. 1997. “Treating drug abusers effectively”. In Cost–Benefit and Cost–Effectiveness Analysis: Issues in the Evaluation of the Treatment of Illicit Drug Abuse, Edited by: EgertsonJA, FoxDM and LeshnerAI. Maiden, MA: Blackwell.
18.
YinD and FormanHP. 1995. Health–care and cost–benefit and cost–effectiveness analysis: An overview. J Vase Interv Radiol, 6: 311–320.
19.
LaveLB and JoshiSV. 1996. Benefit–cost analysis in public health. Annu Rev Public Health, 17: 203–219.
20.
JohannesonM. 1996. Theory and Methods of Economic Evaluation of Health Care, Dordrecht: Kluwer Academic.
21.
TolleyG, KenkelD and FabianR. 1994. Valuing Health for Policy: An Economic Approach, Chicago: The University of Chicago Press.
22.
ZarkinGA, FrenchMT, AndersonDW and BradleyCJ. 1994. A conceptual framework for the economic evaluation of substance abuse interventions. Eval Progr Plann, 17: 409–418.
23.
HansSL. 1999. Demographic and psychosocial characteristics of substance–abusing pregnant women. Clin Perinatol, 26: 55–74.
24.
FlanaganP and KokotailoP. 1999. Adolescent pregnancy and substance use. Clin Perinatol, 26: 185–200.
25.
LiefNR. 1985. The drug user as a parent. Int J Addictions, 20: 63–97.
26.
MarwickC. 1998. Challenging report on pregnancy and drug abuse. JAMA, 280: 1039–1040.
27.
StichlerJF, WeissM and WightNE. 1998. Examining the “cost”; of substance abuse in pregnancy: Patient outcomes and resource utilization. J Perinatol, 18: 384–388.
28.
SvikisD, GoldenAS, HugginsGR, PickensRW, McCaulME, VelezML, RosendaleCT, BroonerRK, GazawayPM, StitzerML and BallCE. 1997. Cost–effectiveness of treatment for drug–abusing pregnant women. Drug Alcohol Depend, 45: 105–113.
29.
SvikisD, McCaulM, FengT, StuartM, FoxM and StokesE. 1998. Drug dependence during pregnancy: Effect of an on–site support group. J Reprod Med, : 799–805.
30.
AndersonDW, BowlandBJ, CartwrightWS and BassinG. 1998. Service–level costing of drug abuse treatment. J Subst Abuse Treat, 15: 201–211.
31.
GoodmanAC, HolderHD, NishiuraE and HankinJR. 1992. An analysis of short–term alcoholism treatment cost functions. Med Care, 30: 795–810.
32.
GoodmanAC, NishiuraE, HankinJR, HolderHD and TilfordJM. 1996. Long–term alcoholism treatment costs. Med Care Res Rev, 53: 441–464.
33.
GoodmanAC, NishiuraE and HankinJR. 1998. Short–term drug abuse treatment costs and utilization: A multi–employer analysis. Med Care, 36: 1214–1227.
34.
FrenchMT, DunlapLJ, ZarkinGA, McGearyKA and McLellanAT. 1997. A structured instrument for estimating the economic cost of drug abuse treatment. The drug abuse treatment cost analysis program (DATCAP). J Subst Abuse Treat, 14: 1–11.
35.
FrenchMT and McGearyKA. 1997. Estimating the economic cost of substance abuse treatment. Health Econ, 6: 539–544.
36.
SaloméHJ, FrenchMT and GalanterM. 2000. “Using cost and financing instruments for economic evaluation of substance abuse treatment services”. In Recent Developments in Alcoholism, Vol XIV: Services Research in the Era of Managed Care, Section 3, Vol XIV, New York: Plenum Press.
37.
HolderHD and ShachtmanRD. 1987. Estimating health care savings associated with alcoholism treatment. Alcohol Clin Exp Res, 11: 66–73.
38.
FrenchMT, MauskopfJE, TeagueJL and RolandEJ. 1996. Estimating the dollar value of health outcomes from drug–abuse interventions. Med Care, 34: 890–910.
39.
RajkumarAS and FrenchMT. 1997. Drug abuse, crime costs, and the economic benefits of treatment. J Quant Crim, 13: 291–323.
40.
HarwoodHJ, HubbardRL, CollinsJ and RachalJV. 1995. A cost–benefit analysis of drug abuse treatment. Res Law Policy Studies, 3: 191–214.
41.
MauserE, Van StelleKR and MobergDP. 1994. The economic impact of diverting substance–abusing offenders into treatment. Crime Deliquency, 40: 568–588.
42.
PlotnickRD. 1994. Applying benefit–cost analysis to substance use prevention programs. Int J Addict, 29: 339–359.
43.
SirotnikKA and BaileyRC. 1975. A cost–benefit analysis for a multi–modality heroin treatment project. Int J Addict, 10: 443–451.
44.
TabbushV. 1986. The Effectiveness and Efficiency of Publicly funded Drug Abuse Treatment and Prevention Programs in California: A benefit–cost Analysis, University of California Press.
45.
GersteinDR, JohnsonRA, HarwoodHJ, FountainHK, SuterN and MalloyK. 1994. Evaluating Recovery Services: The California Drug and Alcohol Treatment Assessment (CALDATA), General Report, Sacramento, CA: California Department of Alcohol and Drug Program.
46.
Institute of Medicine (IOM), GusteinD and HarwoodH, eds. 1990. Treating Drug Problems: A Study of the Evolution, Effectiveness, and Financing of Public and Private Drug Treatment Systems, Washington, DC: National Academy Press.
47.
McLellanAT. 1980. An improved diagnostic evaluation instrument for substance abuse patients. J Nerv Ment Dis, 168: 26–33.
48.
McLellanTA, KushnerHMetzgerD. 1992. The fifth edition of the Addiction Severity Index. J Subst Abuse Treat, 9: 199–213.
49.
RosserR and KindP. 1978. A scale of valuations for status of illness: Is there a social consensus?. Int J Epidemiol, 7: 347–358.
50.
MauskopfJA and FrenchMT. 1991. Estimating the value of avoiding morbidity and mortality from foodborne illnesses. Risk Analys, 11(4): 619–632.
51.
MauskopfJA, BradleyCJ and FrenchMT. 1991. Benefit–cost analysis of hepatitis B vaccine programs for occupationally exposed workers. J Occup Med, 33(6): 691–698.
52.
American Hospital Association. 2000. American Hospital Association Hospital Statistics, Chicago: American Hospital Association.
53.
1999. Physician Fee Schedule for Arkansas State, American Medical Association.
54.
HarwoodH, FountainD and LivermoreG. The Economic Costs of Alcohol and Drug Abuse in the United States, 1992, 98–4327. Rockville, MD: National Institute on Drug abuse and National Institute on Alcohol Abuse and Alcoholism. 1998
55.
BallJC and RossA. 1991. “The Effectiveness of Methadone Maintenance Treatment”. In Patients, Programs, Services, and Outcome, New York: Springer.
56.
StataCorp. 1999. “Stata Statistical Software: Release 6.0”. College Station, TX: Stata Corporation.
57.
RouseB, KozelN and RichardsL, eds. 1985. Self–Report Methods of Estimating Drug Use: Meeting Current Challenges to Validity, Rockville, MD: National Institute on Drug Abuse.
58.
DrakeS. 1998. Self–report among injecting drug users: A review. Drug Alcohol Depend, 51: 253–263.
59.
WeatherbyNL, NeedleR, CesariH, BoothR, McCoyCB, WattersJK, WilliamsM and ChitwoodDD. 1994. Validity of self–reported drug use among injection drug users and crack cocaine users recruited through street outreach. Eval Progr Plann, 17: 347–355.
60.
BloseJO and HolderHD. 1991. The utilization of medical care by treated alcoholics: Longitudinal patterns by age, gender, and type of care. J Subst Abuse, 3: 13–27.
61.
HolderHD, LennoxRD and BloseJD. 1992. The economic benefits of alcoholism treatment: A summary of twenty years of research. J Employee Assist Res, 1: 63–82.
62.
HolderHD and BloseJO. 1992. The reduction of healthcare costs associated with alcoholism treatment: A 14–year longitudinal analysis study. J Stud Alcohol, 53: 293–302.
